Bromochloromethane (BCM), an inhibitor of methanogenesis, has been used in animal production. However, little is known about its impact on the intestinal microbiota and metabolic patterns. The present study aimed to investigate the effect of BCM on the colonic bacterial community and metabolism by establishing a Wistar rat model. Twenty male Wistar rats were randomly divided into two groups (control and treated with BCM) and raised for 6 weeks. Bacterial fermentation products in the cecum were determined, and colonic methanogens and sulfate-reducing bacteria (SRB) were quantified. The colonic microbiota was analyzed by pyrosequencing of the 16S rRNA genes, and metabolites were profiled by gas chromatography and mass spectrometry. The results showed that BCM did not affect body weight and feed intake, but it did significantly change the intestinal metabolic profiles. Cecal protein fermentation was enhanced by BCM, as methylamine, putrescine, phenylethylamine, tyramine, and skatole were significantly increased. Colonic fatty acid and carbohydrate concentrations were significantly decreased, indicating the perturbation of lipid and carbohydrate metabolism by BCM. BCM treatment decreased the abundance of methanogen populations, while SRB were increased in the colon. BCM did not affect the total colonic bacterial counts but significantly altered the bacterial community composition by decreasing the abundance of actinobacteria, acidobacteria, and proteobacteria. The results demonstrated that BCM treatment significantly altered the microbiotic and metabolite profiles in the intestines, which may provide further information on the use of BCM in animal production.
Bromochloromethane (BCM) (CH 2 BrCl, CAS no. 74-97-5) is an analog of dihalogenated methane. Unintentional consumption of this unregulated halomethane as a by-product of disinfection in drinking water is one of the major sources for BCM exposure (1, 2) and has been linked to an increased risk of stomach cancer in Finland (3). Long-term exposure to BCM may cause hepato-and nephrotoxicity in humans. Budnik et al. (4) reviewed 542 publications between 1990 and 2011 and found 91 publications referring to the toxicity of halomethanes on lungs, skin, liver, muscle, spleen, kidneys, and the central nervous system. Although the gastrointestinal tract (GIT) comes in direct contact with ingested BCM, very few studies have focused on the influence of BCM on the GIT, let alone on the intestinal microbiota.BCM can be used as an antimethanogenic compound to decrease methane production. BCM supplementation at 0.3 g/100 kg of body weight (BW) significantly decreased methane production and methanogen abundance in Japanese goats (5), lactating dairy goats (6), steers (7), and Sprague-Dawley (SD) rats (8). BCM inhibits methanogenesis by reacting with cobalamin (9). Cobalamin-dependent enzymes, including cobalamin-dependent methionine synthase (10), methylmalonyl-coenzyme A (CoA) mutase, and glutamate mutase, contribute to the bacterial metabolism under physiological conditions. ...